Cost Implications of Caring for Chronic Kidney Disease: Are Interventions Cost-effective?

Advances in Chronic Kidney Disease

Volumn 17, Issue 3, 2010, Pages 265-270

  Trivedi, Hariprasad ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chronic kidney disease; Cost effectiveness; Treatment

Indexed keywords

CREATININE;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CREATININE BLOOD LEVEL; DIALYSIS; DISABILITY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; INCIDENCE; KIDNEY FAILURE; MEDICARE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RENAL REPLACEMENT THERAPY; REVIEW;

CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HEALTH CARE COSTS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MEDICARE; TIME FACTORS; UNITED STATES;

EID: 77951598508     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.03.007     Document Type: Review

References (12)

1. Saydah S., Eberhardt M., Rios-Burrows N., et al. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. Morb Mortal Wkly Rep 56 (2007) 161-165. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5608a2.htm Accessed February 16, 2010
2. U.S. Renal Data System. USRDS 2009 Annual Data Report (2009), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
3. Chen G.J., and DeBakey M.E. Treatment cost for veterans with chronic kidney disease. Available at:. http://www.hsrd.research.va.gov/research/abstracts.cfm?Project_ID=2141698642 Accessed November 30, 2009
4. Fischer M.J., Stroupe K.T., Browning M.M., et al. Chronic kidney disease is highly prevalent among VA healthcare users. J Am Soc Nephrol 16 (2005) 506A
5. The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., for the collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
8. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
9. Lewis E.J., Hunsicker L.G., Bain R.P., et al., for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
10. Trivedi H., Pang M.M.H., Campbell A., et al. Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 39 (2002) 721-729
11. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
12. Rodby R.A., Lewis E.J., and Firth L.M. for the cooperative study group: An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 19 (1996) 1051-1059